Lamivudine News and Research

RSS
VBDS secondary to nevirapine use in HIV-positive, pregnant female: Report

VBDS secondary to nevirapine use in HIV-positive, pregnant female: Report

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Tibotec submits NDA for TMC278 anti-HIV compound to FDA

Tibotec submits NDA for TMC278 anti-HIV compound to FDA

Tibotec reports Phase 3 trial results of TMC278 vs. EFV in treatment-naive HIV-1-infected adults

Tibotec reports Phase 3 trial results of TMC278 vs. EFV in treatment-naive HIV-1-infected adults

Shionogi-ViiV Healthcare to advance '572 inhibitor into Phase III clinical trials

Shionogi-ViiV Healthcare to advance '572 inhibitor into Phase III clinical trials

Antiviral therapy prevents recurrence of HCC, extends patients' lives, researchers report

Antiviral therapy prevents recurrence of HCC, extends patients' lives, researchers report

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Kun Run Biotechnology obtains China SFDA manufacturing approval for Entecavir

Kun Run Biotechnology obtains China SFDA manufacturing approval for Entecavir

Infant nevirapine more effective in preventing HIV transmission than maternal antiretroviral therapy

Infant nevirapine more effective in preventing HIV transmission than maternal antiretroviral therapy

Gilead Sciences doses first patient in Quad Phase III clinical program

Gilead Sciences doses first patient in Quad Phase III clinical program

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

Gilead Sciences’ “Quad” regimen for HIV exhibits antiretroviral activity comparable to Atripla

Gilead Sciences’ “Quad” regimen for HIV exhibits antiretroviral activity comparable to Atripla

Phase II clinical trial of Gilead Sciences' elvitegravir, GS 9350 and Truvada meets primary objective

Phase II clinical trial of Gilead Sciences' elvitegravir, GS 9350 and Truvada meets primary objective

Enrollment of patients for Phase I/IIa clinical study of Interleukin-7 commenced

Enrollment of patients for Phase I/IIa clinical study of Interleukin-7 commenced

Interim data from Bristol-Myers Squibb's BARACLUDE study for chronic hepatitis B patients

Interim data from Bristol-Myers Squibb's BARACLUDE study for chronic hepatitis B patients

Gilead Sciences to present Viread Phase III clinical trial data

Gilead Sciences to present Viread Phase III clinical trial data

Merck Frosst Canada announces the use of ISENTRESS for treating HIV-1 infected adults

Merck Frosst Canada announces the use of ISENTRESS for treating HIV-1 infected adults

GlaxoSmithKline to allow Apotex continue manufacturing their drug in Rwanda

GlaxoSmithKline to allow Apotex continue manufacturing their drug in Rwanda

FDA Advisory Committee approves use of Selzentry tablets in combination with HIV therapy

FDA Advisory Committee approves use of Selzentry tablets in combination with HIV therapy

Matrix Laboratories receives tentative FDA approval for its NDA

Matrix Laboratories receives tentative FDA approval for its NDA

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.